*EMBARGOED All research presented at the 2023 ACG Annual Scientific Meeting and Postgraduate Course is strictly embargoed until Sunday, October 22, 2023, at 3:00 pm PT.
Oral 13 – Treatment Success for IBS-C Symptoms Increases with Duration of Therapy
Monday, October 23, 2023 | 2:35 PM – 2:45 PM PT | Location: Ballroom A
Author Insight from Brian E. Lacy, MD, PhD, FACG, Mayo Clinic
What’s new here and important for clinicians?
- Patient response rates to treatment with tenapanor, both in terms of constipation and abdominal symptom relief, increase with continued therapy.
- In terms of complete spontaneous bowel movements (CSBMs), 52.3% of patients responded to treatment at week 2, increasing to 76.7% of patients at week 12.
- In terms of abdominal symptoms, 33.2%-36.3% of patients responded to treatment at week 2, increasing to 57.8-64.3% of patients at week 12.
- A significant proportion of patients will have an early, positive response to tenapanor treatment. With continued therapy, a greater proportion of patients achieve a positive response.
- Clinicians and patients should have clear expectations about onset of action. If tenapanor therapy is discontinued at 3-4 weeks, a large percentage of patients will miss the opportunity for symptom relief.
- Don’t give up too early; give patients a fair therapeutic trial.
What do patients need to know?
- It is important to stay on tenapanor therapy because you may miss the opportunity for symptom relief if you discontinue too early.
- A number of patients require up to 12 weeks of therapy to get adequate IBS-C symptom relief.
Read the Abstract
Brian E. Lacy, MD, PhD, FACG, Mayo Clinic
lacy.brian [at] mayo.edu
Media Interview Requests
To arrange an interview with any ACG experts or abstract authors, please contact Becky Abel of ACG via email at mediaonly [at] gi.org or by phone at 301-263-9000.